A Randomised Phase II Study of Zimberelimab Anti-PD1 immunOtherapy +/- Domvanalimab Anti-TIGIT Immunotherapy in Resectable Mismatch Repair Deficient Gastric and Gastro-oesophageal Junctional AdenoCarcinoma

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 29 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Domvanalimab (Primary) ; Zimberelimab (Primary)
Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
Focus Proof of concept; Therapeutic Use
Acronyms ZODIAC

Most Recent Events

24 Jan 2025 Planned primary completion date changed from 1 Sep 2026 to 1 Feb 2027.
24 Jan 2025 Planned initiation date changed from 1 Apr 2024 to 31 Jan 2025.
12 Feb 2024 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight